Clinical Edge Journal Scan

High temporal and spatial resolution improves BC detection in women with high background parenchymal enhancement


 

Key clinical point: In women with high levels of background parenchymal enhancement (BPE), a simultaneous high-temporal/high-spatial resolution (HTHS) magnetic resonance imaging (MRI) protocol detected an additional 15.7 cases of breast cancer (BC) per 1000 patients than the standard high-spatial resolution MRI protocol while concomitantly decreasing the rate of unnecessary biopsies by ~10%.

Major finding: HTHS vs standard protocol improved the BC detection rate per 1000 patients (23.6 vs 7.9; P = .021), increased the positive predictive value of biopsy (16.0% vs 6.3%; P = .014), and decreased the rate of unnecessary biopsies by 9.8%.

Study details: This retrospective study included 1414 women with 1481 high-BPE examinations.

Disclosures: This study was supported partly by the US National Cancer Institute. JS Sung, K Feigin, and K Pinker declared serving in leadership roles and consulting roles or as members of speakers’ bureaus of or receiving research funding from various sources.

Source: Eskreis-Winkler S et al. High-temporal/high-spatial resolution breast magnetic resonance imaging improves diagnostic accuracy compared with standard breast magnetic resonance imaging in patients with high background parenchymal enhancement. J Clin Oncol. 2023 (Aug 10). doi: 10.1200/JCO.22.00635

Recommended Reading

Breast cancer: Hope in sight for improved tamoxifen therapy?
MDedge Hematology and Oncology
No link between most cancers and depression/anxiety: Study
MDedge Hematology and Oncology
Do AI chatbots give reliable answers on cancer? Yes and no
MDedge Hematology and Oncology
Mammography breast density reporting: What it means for clinicians
MDedge Hematology and Oncology
AI mammogram screening is equivalent to human readers
MDedge Hematology and Oncology
Exercise tied to lower mortality risk across cancer types
MDedge Hematology and Oncology
Luminal A BC patients can skip radiotherapy after breast-conserving surgery
MDedge Hematology and Oncology
Giredestrant shows promising outcomes in HR+ /HER2− BC in phase 2 study
MDedge Hematology and Oncology
Metastatic BC: Meaningful clinical benefit with trifluridine/tipiracil in phase 2 study
MDedge Hematology and Oncology
TNBC: Greater efficacy of neoadjuvant apatinib + dose-dense paclitaxel + carboplatin vs dose-dense paclitaxel + carboplatin
MDedge Hematology and Oncology